Soligenix, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing; it does not provide a standalone fourth-quarter financial summary. Soligenix is a clinical-stage biopharmaceutical company with Specialized BioTherapeutics and Public Health Solutions segments. It reported no approved products and relies mainly on government contracts and grants, equity offerings, and debt financing.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $2.36 million | $4.63 million |
| Gross profit / margin | $0.54 million / 23% | $1.06 million / 33% |
| Research and development expense | $10.15 million | $8.12 million |
| General and administrative expense | $3.98 million | $3.48 million |
| Operating loss | $18.59 million | $10.54 million |
| Net loss | $17.69 million | $9.36 million |
| Net loss per share | $0.64 | $0.48 |
| Cash used in operating activities | $11.45 million | $7.51 million |
| Cash and cash equivalents at year-end | $18.68 million | $5.42 million |
| Working capital at year-end | $13.39 million | $1.18 million |
Revenue consisted of contract revenue ($1.93 million) and grant revenue ($0.43 million), not product sales. The company’s $5.0 million SGX301 milestone share issuance to Hy Biopharma was recorded as research and development expense. The filing does not report a conventional product gross margin; the gross margin shown is on contract and grant revenue.
Financing activities provided $24.68 million in cash, including $14.20 million net proceeds from the at-the-market (ATM) equity program, $10.0 million from the first tranche of Pontifax convertible debt, and $0.42 million from a Paycheck Protection Program loan. Year-end liabilities totaled $16.15 million, including $9.86 million net convertible debt, $0.42 million of PPP loan balances, and lease liabilities. Pontifax debt bears 8.47% interest on amounts borrowed, has a two-year interest-only period, and matures June 15, 2025; it is secured by substantially all assets other than intellectual property. The PPP loan bears 0.98% interest and forgiveness is not assured.
Material changes and developments
- Net loss increased 89% year over year, primarily reflecting higher spending on pivotal SGX301 and SGX942 trials and the $5.0 million SGX301 milestone expense. Revenue fell 49%, mainly as grants and contracts ended and the two pivotal trials completed.
- SGX301 (synthetic hypericin for cutaneous T-cell lymphoma, or CTCL) met its Phase 3 primary endpoint in Cycle 1 (p=0.04): 16% of treated patients versus 4% on placebo achieved the defined lesion response. Response rates increased with longer treatment, reaching 49% among the subset treated for 18 weeks. The company planned to pursue an NDA and U.S. commercialization; FDA approval had not been obtained at the filing date.
- SGX942 (dusquetide for severe oral mucositis in head and neck cancer) missed the Phase 3 primary endpoint’s prespecified statistical significance threshold. Median severe mucositis duration was 8 days with treatment versus 18 days with placebo, but the result was not statistically significant. A per-protocol analysis showed a 9-day versus 18-day median (p=0.049); management said it was analyzing the results and might discuss responsive patient subsets with regulators.
- RiVax’s Phase 1c study was suspended in January 2020 after the manufacturer reported that drug substance testing was outside specification and initial release results used an improper test method. Two participants had received doses before the notice. The NIH did not exercise the final contract option, and the $21.2 million contract expired in February 2021.
- Soligenix filed arbitration against Emergent entities seeking more than $19 million in damages related to RiVax manufacturing and quality failures. Emergent denied the allegations; the filing gives no assurance of recovery. The company did not accrue approximately $331,000 of Emergent invoices because management considered payment not probable.
- Public Health Solutions programs included preclinical CiVax, a COVID-19 vaccine candidate, and ThermoVax vaccine-stabilization work, alongside RiVax and SGX943. A $1.5 million NIAID grant awarded in December 2020 supported COVID-19 and Ebola vaccine candidate work. Funding remains dependent on government awards and options.
Outlook, liquidity, and key risks
Management expected 2021 research and development spending of approximately $10.7 million before reimbursements, with about $0.8 million expected to be reimbursed under existing awards. As of December 31, 2020, $2.16 million of contract and grant funding remained available, subject to agency terms. The company reported that, based on its budget, cash, grant funding, available financing, and ATM capacity, it expected to fund operations for at least 12 months from issuance of the financial statements. Its risk-factor discussion separately cited expected operations through at least March 31, 2022, based on projected needs and funding sources; neither statement removes the need for future financing.
Subsequent to year-end, through March 30, 2021, Soligenix sold 9,376,792 shares through the ATM at a weighted average $1.75 per share. The filing reported approximately $30.4 million of cash and cash equivalents as of March 30, 2021, up to $10.0 million of Pontifax financing remaining (including a $5.0 million tranche conditional on initial CTCL NDA filing), and about $2.1 million of ATM capacity remaining. These sources involve potential dilution, debt obligations, or conditions.
- The company has incurred substantial losses, had an accumulated deficit of $193.2 million at year-end, and expects future losses. It has no product revenue and may need additional capital, partnerships, or government funding to sustain development.
- Development, regulatory approval, manufacturing, commercialization, reimbursement, and market acceptance are uncertain. Soligenix outsources manufacturing and clinical work and notes that key drug substances rely on single suppliers.
- Government funding may be reduced or terminated; COVID-19 could disrupt materials sourcing, manufacturing, trial operations, and patient availability.
- Common shares outstanding rose from 21.75 million at year-end 2019 to 30.64 million at year-end 2020. The filing also identifies warrants, options, convertible debt, and possible further ATM sales as sources of potential dilution.
- Other exposures include debt covenants and repayment, uncertain arbitration proceeds, license and milestone obligations, and the possible unavailability of New Jersey tax-credit/NOL sale proceeds. No cash dividends were anticipated.
Most important facts for investors to verify
- SGX301’s full Phase 3 dataset, regulatory filing status, FDA review path, and any subsequent decision on approval or commercialization.
- SGX942’s complete Phase 3 results and management’s next steps with the FDA and EMA after missing the primary endpoint.
- Current cash, operating cash burn, remaining ATM capacity, subsequent share issuance, Pontifax draw conditions and covenants, and the resulting dilution and debt-service burden.
- Status and expected timing of the Emergent arbitration, including any rulings, settlement, or recoverable damages; no recovery is assured.
- Whether remaining government grants and contracts are renewed or terminated, and whether the RiVax manufacturing issue is resolved sufficiently to restart clinical development.